CSL Behring News
CSL Behring News
First SCIg Approved for CIDP
HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP
CSL Donates to Indonesian Relief Operations
CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in sup…
CSL a Top 100 Company for Diversity & Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global D…
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to t…
Patient Enrolled in CSL112 Clinical Trial
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medi…